Structure Therapeutics Inc. American Depositary Shares

Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company that develops oral small molecule therapeutics for chronic diseases with unmet medical needs in the United States. Its lead candidate, GSBR-1290, is an oral biased small molecule agonist of the glucagon-like peptide-1 receptor in two phase 2 trials for obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist in a phase 1 trial for obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist targeting the lysophosphatidic acid 1 receptor for idiopathic pulmonary fibrosis. Additional programs include a glucose-dependent insulinotropic polypeptide receptor (GIPR) program and a GCG program. The company was formerly known as ShouTi Inc., was incorporated in 2016, and is headquartered in South San Francisco, California.